{"transactions":[{"id":4620682,"issuer":{"id":7094,"kind":"organization","name":"Inmune Bio, Inc.","symbol":"INMB"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2026-09-17T17:44:11.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":2.33,"expiration_date":"2036-09-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-100877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026100877/ownership.xml","form_type":"4"}},{"id":751451,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-03T20:10:45.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement. The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan."}],"balance_after":235000,"derivative":{"exercise_price":1.12,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001493152-26-027054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226027054/ownership.xml","form_type":"4"}},{"id":1087229,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-07-15T16:22:47.000Z","date":"2025-07-11","kind":"grant","planned":false,"acquired":true,"shares":11066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":11066,"derivative":{"exercise_price":0.59,"expiration_date":"2035-07-11","underlying":"Common Stock","underlying_shares":11066},"source":{"system":"sec-edgar","filing":"0001641172-25-019728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000164117225019728/ownership.xml","form_type":"4"}},{"id":1397788,"issuer":{"id":8471,"kind":"organization","name":"Onconetix, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-30T19:11:18.000Z","date":"2024-09-26","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award granted to the Reporting Person pursuant to the Issuer's 2022 Equity Incentive Plan, as amended. The award will vest in full on August 31, 2025 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date."}],"balance_after":3477,"source":{"system":"sec-edgar","filing":"0001213900-24-083522","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000121390024083522/ownership.xml","form_type":"4"}},{"id":1451678,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-18T21:35:06.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option disclosed on this Form 4 was not previously reported due to an administrative oversight."},{"field":"shares","element":"transactionShares","label":"F2","text":"Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests annually in three equal installments commencing on May 24, 2024."}],"balance_after":132,"derivative":{"exercise_price":152.46,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":132},"source":{"system":"sec-edgar","filing":"0001493152-24-028403","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000149315224028403/ownership.xml","form_type":"4"}},{"id":1459902,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-07-03T18:33:15.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":1289,"price":1.07,"value":1379.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.05 - $1.16, inclusive. The Reporting Person undertakes to provide Entero Therapeutics, Inc. (\"Entero\"), any security holder of Entero, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth\nin this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":35816,"source":{"system":"sec-edgar","filing":"0001104659-24-077713","document":"tm2418821-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924077713/tm2418821-1_4seq1.xml","form_type":"4"}},{"id":1467978,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase shares of common stock","published_at":"2024-06-27T22:55:36.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":48137,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48137,"derivative":{"exercise_price":1.61,"exercise_date":"2024-06-25","expiration_date":"2034-06-25","underlying":"Common stock","underlying_shares":48137},"source":{"system":"sec-edgar","filing":"0001731122-24-001037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224001037/ownership.xml","form_type":"4"}},{"id":1549503,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-04-03T21:14:29.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":174,"price":4.2294,"value":735.9156,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":37105,"source":{"system":"sec-edgar","filing":"0001104659-24-043156","document":"tm2411006-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924043156/tm2411006-1_4seq1.xml","form_type":"4"}},{"id":1568586,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-03-19T20:13:22.000Z","date":"2024-03-15","kind":"sale","planned":false,"acquired":false,"shares":1887,"price":4.96,"value":9359.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.90 - $5.175, inclusive. The Reporting Person undertakes to provide First Wave BioPharma, Inc. (\"First Wave\"), any security holder of First Wave, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":37279,"source":{"system":"sec-edgar","filing":"0001104659-24-036143","document":"tm249257-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924036143/tm249257-2_4seq1.xml","form_type":"4"}},{"id":1567618,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-19T15:18:06.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":28196,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28196,"derivative":{"exercise_price":2.66,"exercise_date":"2025-03-06","expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":28196},"source":{"system":"sec-edgar","filing":"0001731122-24-000455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112224000455/ownership.xml","form_type":"4"}},{"id":1677864,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2024-01-17T21:01:40.000Z","date":"2024-01-12","kind":"sale","planned":false,"acquired":false,"shares":166,"price":4.2,"value":697.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":39166,"source":{"system":"sec-edgar","filing":"0001104659-24-004458","document":"tm243514-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924004458/tm243514-1_4seq1.xml","form_type":"4"}},{"id":1692344,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2024-01-04T00:55:46.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On January 2, 2024, the Reporting Person was granted 20,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":39332,"source":{"system":"sec-edgar","filing":"0001104659-24-001026","document":"tm241923-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924001026/tm241923-1_4seq1.xml","form_type":"4"}},{"id":1692343,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman, President and CEO"}}],"security":"Common Stock","published_at":"2024-01-04T00:55:46.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":17660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 29, 2023, the Reporting Person was granted 17,660 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":19332,"source":{"system":"sec-edgar","filing":"0001104659-24-001026","document":"tm241923-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924001026/tm241923-1_4seq1.xml","form_type":"4"}},{"id":1763589,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-06T20:04:21.000Z","date":"2023-10-04","kind":"sale","planned":false,"acquired":false,"shares":2764,"price":0.29,"value":801.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.291 to $0.293. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":33397,"source":{"system":"sec-edgar","filing":"0001104659-23-107481","document":"tm2327991-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465923107481/tm2327991-1_4seq1.xml","form_type":"4"}},{"id":1836106,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-05T20:27:46.000Z","date":"2023-07-03","kind":"sale","planned":false,"acquired":false,"shares":3349,"price":1.54,"value":5157.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.49 to $1.61. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."}],"balance_after":36161,"source":{"system":"sec-edgar","filing":"0001104659-23-078144","document":"tm2320603-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465923078144/tm2320603-1_4seq1.xml","form_type":"4"}},{"id":1871671,"issuer":{"id":8471,"kind":"organization","name":"Onconetix, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-01T21:10:19.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":6360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock award granted to the Reporting Person pursuant to the Issuer's 2022 Equity Incentive Plan, as amended. The award will vest in full on May 31, 2024 so long as the Reporting Person continues to serve as a non-employee director of the Issuer until such date."}],"balance_after":6360,"source":{"system":"sec-edgar","filing":"0001213900-23-045323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000121390023045323/ownership.xml","form_type":"4"}},{"id":1925056,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-05T20:07:26.000Z","date":"2023-04-03","kind":"sale","planned":false,"acquired":false,"shares":3347,"price":2.5,"value":8367.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units (\"RSUs\"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023."}],"balance_after":39510,"source":{"system":"sec-edgar","filing":"0001104659-23-042156","document":"tm2311820-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465923042156/tm2311820-1_4seq1.xml","form_type":"4"}},{"id":1926994,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-04-04T20:07:38.000Z","date":"2023-03-06","kind":"grant","planned":false,"acquired":true,"shares":64655,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64655,"derivative":{"exercise_price":1.16,"exercise_date":"2024-03-06","expiration_date":"2033-03-06","underlying":"Common Stock","underlying_shares":64655},"source":{"system":"sec-edgar","filing":"0001731122-23-000571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112223000571/ownership.xml","form_type":"4"}},{"id":2062603,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-05T14:00:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 3, 2023, the Reporting Person was granted 300,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning March 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001104659-23-001228","document":"tm231522-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000110465923001228/tm231522-5_4seq1.xml","form_type":"4"}},{"id":2252837,"issuer":{"id":8471,"kind":"organization","name":"Onconetix, Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-05-27T10:40:49.000Z","date":"2022-05-04","kind":"grant","acquired":true,"shares":50575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options (the \"Options\") were granted to Mr. Sapirstein on May 4, 2022. The Options vest and become exercisable as follows: (A) with respect to 45,920 of the Options: (i) 1,912 Options vested immediately upon grant; (ii) 956 Options vest at the end of each calendar month from the date of issuance through January 31, 2026 and (iii) the remaining 988 Options vest on February 28, 2026 and (B) with respect to 4,655 of the Options: (i) (1) 774 of the Options vested immediately upon grant; (ii) 388 Options vest at the end of each calendar month from the date of issuance through February 28, 2023 and (iii) the remaining 389 Options vest on March 31, 2023."}],"balance_after":50575,"derivative":{"exercise_price":6.45,"expiration_date":"2032-05-04","underlying":"Common Stock, par value $0.00001 per share","underlying_shares":50575},"source":{"system":"sec-edgar","filing":"0001213900-22-029995","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000121390022029995/ownership.xml","form_type":"4"}},{"id":2454289,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"officer_title":"PRES, CEO & CHAIRMAN OF BOARD"}}],"security":"Stock option (right to buy)","published_at":"2022-01-04T02:07:24.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 36 equal monthly installments over a term of three (3) years beginning on the date of grant, conditioned on Mr. Sapirstein's continued employment by First Wave BioPharma, Inc. on the applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.45,"expiration_date":"2032-01-03","underlying":"Common stock, par value $0.0001 per share","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-22-000302","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000114036122000302/form4.xml","form_type":"4"}},{"id":2644685,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES, CEO & CHAIRMAN OF BOARD"}}],"security":"Stock options (right to buy)","published_at":"2021-07-02T21:07:14.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 30, 2021, the board of directors of AzurRx BioPharma, Inc. (the \"Company\") rescinded and cancelled stock option awards previously made to Mr. Sapirstein on July 16, 2020 covering 900,000 shares under the Company's Amended and Restated 2014 Omnibus Equity Incentive Plan and granted new stock options under the Company's 2020 Omnibus Equity Incentive Plan, as amended and restated, on substantially similar terms to the rescinded stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests (i) with respect to 300,000 shares over a term of 18 months in 18 equal monthly installments starting with the first monthly installment on February 16, 2022, (ii) with respect to 200,000 shares immediately, and (iii) with respect to 400,000 shares, if at all, upon the achievement of certain performance targets. Vesting is conditioned on Mr. Sapirstein's continued employment by the Company on the applicable vesting date."}],"balance_after":900000,"derivative":{"exercise_price":0.85,"expiration_date":"2031-06-30","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001415889-21-003426","document":"form4-07022021_020749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588921003426/form4-07022021_020749.xml","form_type":"4"}},{"id":2644684,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRES, CEO & CHAIRMAN OF BOARD"}}],"security":"Stock options (right to buy)","published_at":"2021-07-02T21:07:14.000Z","date":"2021-06-30","kind":"other","acquired":false,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 30, 2021, the board of directors of AzurRx BioPharma, Inc. (the \"Company\") rescinded and cancelled stock option awards previously made to Mr. Sapirstein on July 16, 2020 covering 900,000 shares under the Company's Amended and Restated 2014 Omnibus Equity Incentive Plan and granted new stock options under the Company's 2020 Omnibus Equity Incentive Plan, as amended and restated, on substantially similar terms to the rescinded stock options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options vest with respect to 300,000 shares in 18 equal monthly installments over a term of 18 months beginning 19 months after the grant of such options on July 16, 2020, and with respect to the remaining shares, if at all, upon the achievement of certain performance targets. Vesting is conditioned on Mr. Sapirstein's continued employment by the Company on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 30, 2021, the board of directors of AzurRx BioPharma, Inc. (the \"Company\") rescinded and cancelled stock option awards previously made to Mr. Sapirstein on July 16, 2020 covering 900,000 shares under the Company's Amended and Restated 2014 Omnibus Equity Incentive Plan and granted new stock options under the Company's 2020 Omnibus Equity Incentive Plan, as amended and restated, on substantially similar terms to the rescinded stock options."}],"balance_after":300000,"derivative":{"exercise_price":0.85,"expiration_date":"2030-07-15","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001415889-21-003426","document":"form4-07022021_020749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588921003426/form4-07022021_020749.xml","form_type":"4"}},{"id":2774538,"issuer":{"id":95786,"kind":"organization","name":"MARIZYME, INC.","symbol":"MRZM"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Options","published_at":"2021-03-23T20:30:37.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":125000,"price":1.25,"value":156250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Consists of 125,000 options for common stock granted to the reporting person under an agreement dated March 5, 2021. The options vest quarterly in equal installments starting March 5, 2021."}],"balance_after":1350000,"derivative":{"exercise_price":1.25,"exercise_date":"2024-03-05","expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-21-006628","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413754/000149315221006628/ownership.xml","form_type":"4"}},{"id":2794158,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-03-12T01:02:35.000Z","date":"2021-03-06","kind":"grant","acquired":true,"shares":19894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 6, 2021, Mr. Sapirstein was granted an option to purchase 19,894 shares of common stock of Enochian Biosciences Inc., said option to vest on March 6, 2022."}],"balance_after":19894,"derivative":{"exercise_price":3.77,"exercise_date":"2022-03-06","expiration_date":"2031-03-06","underlying":"Common Stock","underlying_shares":19894},"source":{"system":"sec-edgar","filing":"0001731122-21-000358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112221000358/ownership.xml","form_type":"4"}},{"id":3079549,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Series B Warrants","published_at":"2020-07-21T01:50:38.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":64935,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sapirstein purchased 12.987012 shares of Series B Stock, together with Series B Warrants to purchase 64,935 shares of Common Stock, for cash consideration of $7,700.00 per share of Series B Stock. The amount of the Series B Warrants is equal to 50% of the shares of Common Stock into which the Series B Stock is initially convertible."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Mr. Sapirstein cannot convert the Series B Stock or exercise the warrants (the \"Series B Warrants\") until the Company obtains stockholder approval pursuant to Nasdaq Listing Rule 5635(c) and 5635(d) (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"In the event that the Company has not obtained the Stockholder Approval on or prior to the Approval Deadline, Mr. Sapirstein shall surrender the Series B Warrants to the Company for cancellation in connection with the Company's repurchase of the Series B Stock described above."}],"balance_after":64935,"derivative":{"exercise_price":0.85,"expiration_date":"2025-07-16","underlying":"Common stock, par value $0.0001 per share","underlying_shares":64935},"source":{"system":"sec-edgar","filing":"0001415889-20-001935","document":"form4-07202020_060729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588920001935/form4-07202020_060729.xml","form_type":"4"}},{"id":3079548,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-07-21T01:50:38.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":12.987,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Company's Series B Preferred Stock, par value $0.0001 per share (the \"Series B Stock\"), is convertible, at Mr. Sapirstein's option, into Common Stock at a conversion rate equal to the quotient of (x) its stated value, which is initially $7,700 per share, divided by (y) the conversion price, which is initially of $0.77 per share of Common Stock, subject in each case to specified adjustments for stock splits, cash or stock dividends, reorganizations, reclassifications other similar events as set forth in the Certificate of Designations for the Series B Stock (the \"Certificate of Designations\"). Each share of Series B Stock also carries a cumulative dividend, accruing daily at a rate of 9.0% per year, payable each June 30 and December 30 arrears, in cash or shares of Series B Stock at the sole option of the Company, as specified in the Certificate of Designations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Mr. Sapirstein purchased 12.987012 shares of Series B Stock, together with Series B Warrants to purchase 64,935 shares of Common Stock, for cash consideration of $7,700.00 per share of Series B Stock. The amount of the Series B Warrants is equal to 50% of the shares of Common Stock into which the Series B Stock is initially convertible."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Mr. Sapirstein cannot convert the Series B Stock or exercise the warrants (the \"Series B Warrants\") until the Company obtains stockholder approval pursuant to Nasdaq Listing Rule 5635(c) and 5635(d) (the \"Stockholder Approval\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Stock has no expiration date. However, if the Company has not obtained the Stockholder Approval on or prior to the 90th day following the issuance date of the Series B Stock (the \"Approval Deadline\"), the Company is required to repurchase the Series B Stock from Mr. Sapirstein at a price equal to 150% of its stated value, as adjusted pursuant to the Certificate of Designations, plus accrued and unpaid dividends thereon to the repurchase date."}],"balance_after":12.987,"derivative":{"exercise_price":0.77,"underlying":"Common stock, par value $0.0001 per share","underlying_shares":129870},"source":{"system":"sec-edgar","filing":"0001415889-20-001935","document":"form4-07202020_060729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588920001935/form4-07202020_060729.xml","form_type":"4"}},{"id":3079547,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock options (right to buy)","published_at":"2020-07-21T01:50:38.000Z","date":"2020-07-16","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 16, 2020, the board of directors of AzurRx BioPharma, Inc. (the \"Company\") awarded Mr. Sapirstein stock options to purchase 1,200,000 shares of the Company's common stock, par value $0.0001 per share (the \"Common Stock\"), pursuant to the Company's 2014 Omnibus Equity Incentive Plan. The stock options vest with respect to 600,000 shares in 36 equal monthly installments over a term of three (3) years beginning on August 16, 2020, and with respect to the remaining shares, if at all, upon the achievement of certain performance targets. Vesting is conditioned on Mr. Sapirstein's continued employment by the Company on the applicable vesting date."}],"balance_after":1200000,"derivative":{"exercise_price":0.85,"expiration_date":"2030-07-15","underlying":"Common stock, par value $0.0001 per share","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001415889-20-001935","document":"form4-07202020_060729.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588920001935/form4-07202020_060729.xml","form_type":"4"}},{"id":3394738,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Options","published_at":"2019-10-11T01:11:23.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Options granted in connection with the Reporting Person's appointment as President and Chief Executive Officer of the Issuer. The options will vest (i) 50,000 upon the Company initiating its next Phase II clinical trial in the United States for MS1819, (ii) 50,000 upon the Company completing its next Phase II clinical trial in the United States for MS1819, (iii) 100,000 upon the Company initiating a Phase III clinical trial in the United States for MS1819 and (iv) 100,000 upon the Company initiating a Phase I clinical trial in the United States for any product other than MS1819."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted in connection with the Reporting Person's appointment as President and Chief Executive Officer of the Issuer. The options will vest (i) 50,000 upon the Company initiating its next Phase II clinical trial in the United States for MS1819, (ii) 50,000 upon the Company completing its next Phase II clinical trial in the United States for MS1819, (iii) 100,000 upon the Company initiating a Phase III clinical trial in the United States for MS1819 and (iv) 100,000 upon the Company initiating a Phase I clinical trial in the United States for any product other than MS1819."}],"balance_after":300000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-10-08","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-19-001167","document":"form4-10102019_061006.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588919001167/form4-10102019_061006.xml","form_type":"4"}},{"id":3394737,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2019-10-11T01:11:23.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents grant of restricted stock issued in connection with the Reporting Person's appointment as President and Chief Executive Officer of the Issuer. The shares of restricted stock will vest (i) 100,000 upon the first commercial sale in the United States of MS1819 and (ii) 100,000 shares upon the total market capitalization of the Company exceeding $1.0 billion for 20 consecutive trading days."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001415889-19-001167","document":"form4-10102019_061006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604191/000141588919001167/form4-10102019_061006.xml","form_type":"4"}},{"id":3429075,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2019-08-26T20:47:01.000Z","date":"2019-08-22","kind":"grant","acquired":true,"shares":9173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 22, 2019, Mr. Sapirstein was granted an option to purchase 9,173 shares of common stock of Enochian Biosciences, Inc., said option to vest on December 10, 2019."}],"balance_after":9173,"derivative":{"exercise_price":6.25,"exercise_date":"2019-12-10","expiration_date":"2029-03-03","underlying":"Common Stock","underlying_shares":9173},"source":{"system":"sec-edgar","filing":"0001731122-19-000516","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112219000516/ownership.xml","form_type":"4"}},{"id":3806424,"issuer":{"id":7981,"kind":"organization","name":"Lunai Bioworks Inc."},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2018-09-27T10:43:28.000Z","date":"2018-09-19","kind":"grant","acquired":true,"shares":5226,"price":5.74,"value":29997.24,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 19, 2018, Mr. Sapirstein was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Mr. Sapirstein's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant."}],"balance_after":12770,"derivative":{"exercise_price":5.74,"exercise_date":"2019-03-06","expiration_date":"2028-09-19","underlying":"Common Stock","underlying_shares":5226},"source":{"system":"sec-edgar","filing":"0001731122-18-000085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112218000085/ownership.xml","form_type":"4"}},{"id":4105064,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-01-05T13:09:23.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":322092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported item represents an award of restricted stock pursuant to the Company's 2013 Equity Incentive Plan.  All of the shares vested upon grant.  Such shares were issued in lieu of a cash bonus to the reporting person."}],"balance_after":492819,"source":{"system":"sec-edgar","filing":"0001104659-18-000924","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465918000924/a4.xml","form_type":"4"}},{"id":4135616,"issuer":{"id":146118,"kind":"organization","name":"RespireRx Pharmaceuticals Inc.","symbol":"RSPI"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options (to purchase shares of Common Stock)","published_at":"2017-12-12T19:38:21.000Z","date":"2017-12-09","kind":"other","acquired":true,"shares":38114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 9, 2017, Mr. Sapirstein forgave all of the accrued but unpaid directors fees to which he was entitled as of September 30, 2017, an aggregate of $55,000.  On that date, the Company granted to Mr. Sapirstein options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000.  These Common Stock Options vested upon issuance."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 9, 2017, Mr. Sapirstein forgave all of the accrued but unpaid directors fees to which he was entitled as of September 30, 2017, an aggregate of $55,000.  On that date, the Company granted to Mr. Sapirstein options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000.  These Common Stock Options vested upon issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 9, 2017, Mr. Sapirstein forgave all of the accrued but unpaid directors fees to which he was entitled as of September 30, 2017, an aggregate of $55,000.  On that date, the Company granted to Mr. Sapirstein options to purchase 38,114 shares of the Company's common stock, with a black-scholes value of $1.44 per option and an aggregate value of $55,000.  These Common Stock Options vested upon issuance."}],"balance_after":38114,"derivative":{"exercise_price":1.45,"expiration_date":"2022-12-09","underlying":"Common Stock","underlying_shares":38114},"source":{"system":"sec-edgar","filing":"0001573202-17-000012","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/849636/000157320217000012/primary_doc.xml","form_type":"4"}},{"id":4260681,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-07-07T17:01:12.000Z","date":"2017-07-06","kind":"grant","acquired":true,"shares":141061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported item represents an award of restricted stock pursuant to the Company's 2013 Equity Incentive Plan.  All of the shares vested upon grant.  Such shares were issued in lieu of a cash bonus to the reporting person."}],"balance_after":170727,"source":{"system":"sec-edgar","filing":"0001104659-17-044100","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465917044100/a4.xml","form_type":"4"}},{"id":4266192,"issuer":{"id":146118,"kind":"organization","name":"RespireRx Pharmaceuticals Inc.","symbol":"RSPI"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options (to purchase shares of Common Stock)","published_at":"2017-07-05T19:37:51.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Common Stock Options vested upon issuance."}],"balance_after":25000,"derivative":{"exercise_price":2,"expiration_date":"2022-06-30","underlying":"common stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001573202-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/849636/000157320217000002/primary_doc.xml","form_type":"4"}},{"id":4396662,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-03-07T16:00:38.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":313898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest in three installments as follows: 104,632 of the options vest on each of March 6, 2018 and 2019 and 104,634 vest on March 6, 2020."}],"balance_after":2761129,"derivative":{"exercise_price":1.48,"expiration_date":"2027-03-06","underlying":"Common Stock","underlying_shares":313898},"source":{"system":"sec-edgar","filing":"0001104659-17-014835","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465917014835/a4.xml","form_type":"4"}},{"id":4396661,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2017-03-07T16:00:38.000Z","date":"2017-03-03","kind":"grant","acquired":true,"shares":313898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest in three installments as follows: 104,632 of the options vest on each of March 3, 2018 and 2019 and 104,634 vest on March 3, 2020."}],"balance_after":2447231,"derivative":{"exercise_price":1.43,"expiration_date":"2027-03-03","underlying":"Common Stock","underlying_shares":313898},"source":{"system":"sec-edgar","filing":"0001104659-17-014835","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465917014835/a4.xml","form_type":"4"}},{"id":4444987,"issuer":{"id":157801,"kind":"organization","name":"Probility Media Corp","symbol":"PBYA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-15T15:48:02.000Z","date":"2016-11-08","kind":"grant","acquired":true,"shares":75000,"price":0.79,"value":59250.0,"ownership":{"direct":true},"balance_after":210000,"source":{"system":"sec-edgar","filing":"0001683168-17-000380","document":"sapirstein_f4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1530981/000168316817000380/sapirstein_f4.xml","form_type":"4"}},{"id":4485772,"issuer":{"id":146118,"kind":"organization","name":"RespireRx Pharmaceuticals Inc.","symbol":"RSPI"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options (to purchase shares of Common Stock)","published_at":"2017-01-20T21:24:38.000Z","date":"2017-01-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Common Stock Options vest in three installments:  25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017."}],"balance_after":25000,"derivative":{"exercise_price":3.9,"expiration_date":"2022-01-18","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001363763-17-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/849636/000136376317000005/primary_doc.xml","form_type":"4"}},{"id":4571690,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2016-10-31T17:39:58.000Z","date":"2016-10-27","kind":"exercise","acquired":false,"shares":16666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fully vested."}],"balance_after":2133334,"derivative":{"exercise_price":1.5,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0001104659-16-153407","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465916153407/a4.xml","form_type":"4"}},{"id":4571689,"issuer":{"id":8208,"kind":"organization","name":"Hepion Pharmaceuticals, Inc.","symbol":"HEPA"},"owners":[{"id":41703,"kind":"person","name":"SAPIRSTEIN JAMES","position":1,"cik":"0001559509","reported_name":"SAPIRSTEIN JAMES","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-10-31T17:39:58.000Z","date":"2016-10-27","kind":"exercise","acquired":true,"shares":16666,"price":1.5,"value":24999.0,"ownership":{"direct":true},"balance_after":29666,"source":{"system":"sec-edgar","filing":"0001104659-16-153407","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559509/000110465916153407/a4.xml","form_type":"4"}}]}